

.....
(Original Signature of Member)

118TH CONGRESS
1ST SESSION

H. R. _____

To amend section 412 of the Federal Food, Drug, and Cosmetic Act to enhance the safeguards applicable with respect to infant formula.

IN THE HOUSE OF REPRESENTATIVES

Ms. PORTER introduced the following bill; which was referred to the Committee on _____

A BILL

To amend section 412 of the Federal Food, Drug, and Cosmetic Act to enhance the safeguards applicable with respect to infant formula.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Safeguarding Kids and
5 Families from Critical Food Disruptions Act of 2023”.

1 **SEC. 2. SAFEGUARDING KIDS AND FAMILIES FROM CRIT-**
2 **ICAL FOOD DISRUPTIONS.**

3 (a) IN GENERAL.—Subsection (e) of section 412 of
4 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
5 350a) is amended to read as follows:

6 “(e)(1) If the manufacturer of an infant formula has
7 knowledge which reasonably supports the conclusion that
8 an infant formula which has been processed by the manu-
9 facturer and which has left an establishment subject to
10 the control of the manufacturer—

11 “(A) may not provide the nutrients required by sub-
12 section (i), or

13 “(B) may be otherwise adulterated or misbranded,
14 the manufacturer shall, within 24 hours, notify the Sec-
15 retary and the Director of the Office of Critical Foods of
16 such knowledge.

17 “(2) If the manufacturer of an infant formula has
18 knowledge which reasonably supports the conclusion that
19 an infant formula which has been processed by the manu-
20 facturer may be adulterated due to pathogen contamina-
21 tion (such as confirmation of a positive analytical result
22 from any in-process or finished product testing), the man-
23 ufacturer shall—

24 “(A) within 24 hours, notify the Secretary and
25 the Director of the Office of Critical Foods of such
26 knowledge, regardless of whether such infant for-

1 mula has left an establishment subject to the control
2 of the manufacturer; and

3 “(B) provide to the Secretary, for the purpose
4 of sequencing, results and isolates from a positive
5 sample of such infant formula.

6 “(3) In submitting a notification under paragraph (1)
7 or (2), a manufacturer shall adhere to any submission re-
8 quirements or procedures specified by the Secretary.

9 “(4) If the Secretary determines that an infant for-
10 mula presents a risk to human health, the manufacturer
11 shall immediately take all actions necessary to cease dis-
12 tribution of such infant formula and recall shipments of
13 such infant formula from all wholesale and retail establish-
14 ments, consistent with recall regulations and guidelines
15 issued by the Secretary.

16 “(5)(A) Not later than 72 hours after receipt by the
17 Director of the Office of Critical Foods of a notification
18 under paragraph (1) or (2), the Director shall contact the
19 manufacturer of the infant formula, or an affiliate thereof
20 in the United States, to discuss corrective action.

21 “(B) If there is a failure of the Director of the Office
22 of Critical Foods to act within 72 hours after receipt of
23 a notification as required by subparagraph (A), the Sec-
24 retary shall immediately notify the appropriate congres-

1 sional committees what, if any, accountability mechanisms
2 were, or will be, invoked for such failure.

3 “(6) The Director of the Office of Critical Foods—

4 “(A) not later than 90 days after receipt by the
5 Director of a notification under paragraph (1) or
6 (2), shall confirm that the manufacturer submitting
7 the notification performed, or is performing, appro-
8 priate corrective action, including a root cause anal-
9 ysis;

10 “(B) in making such confirmation, may collect
11 documentation during an inspection, electronically,
12 or by other means; and

13 “(C) shall notify the appropriate congressional
14 committees if the Director is unable to make such
15 confirmation and what, if any, accountability mecha-
16 nisms were, or will be, invoked for such failure.

17 “(7) Not later than the end of each of calendar years
18 2024, 2025, and 2026, the Secretary shall submit to the
19 Congress a report containing—

20 “(A) the number of notifications received under
21 paragraph (1) or (2) during the fiscal year ending
22 in the respective calendar year;

23 “(B) the average number of hours it took the
24 Director of the Office of Critical Foods to initiate

1 contact, as required by paragraph (5), in response to
2 such notifications;

3 “(C) the longest and shortest time it took the
4 Director of the Office of Critical Foods to so initiate
5 contact;

6 “(D) the average number of days it took the
7 Director of the Office of Critical Foods to confirm
8 corrective action, as required by paragraph (6), in
9 response to such notifications; and

10 “(E) the longest and shortest number of days
11 it took the Director of the Office of Critical Foods
12 to so confirm corrective action.

13 “(8) For purposes of paragraphs (1) and (2), the
14 term ‘knowledge’ as applied to a manufacturer means—

15 “(A) the actual knowledge that the manufac-
16 turer had; or

17 “(B) the knowledge which a reasonable person
18 would have had under like circumstances or which
19 would have been obtained upon the exercise of due
20 care.

21 “(9) For purposes of paragraph (2), the term ‘patho-
22 gen’ means a microorganism of public health signifi-
23 cance.”.

24 (b) TIMING.—

1 (1) NOTIFICATION REQUIREMENTS.—Para-
2 graphs (1), (2), (3), (4), (8), and (9) of subsection
3 (e) of section 412 of the Federal Food, Drug, and
4 Cosmetic Act (21 U.S.C. 350a), as amended by sub-
5 section (a), apply upon the enactment of this Act.

6 (2) RESPONSE BY SECRETARY.—Not later than
7 180 days after the date of enactment of this Act, the
8 Secretary of Health and Human Services, acting
9 through the Director of the Office of Critical Foods,
10 shall establish a process for carrying out paragraphs
11 (5) and (6) of subsection (e) of section 412 of the
12 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
13 350a), as amended by subsection (a), and begin im-
14 plementation of such process.